Neumora Therapeutics
precision strategy for in amyotrophic lateral sclerosis als incorporates drug specific properties to define potential best responders | Neumora Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
September 2023
Slide
23 of 32
Related slides by other companies
Tietoevry
Investor Presentation
July 2022
financial targets new strategy support potential for enhanced performance als | Tietoevry
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights